Chronic Lymphocytic Leukemia Peer-to-Peer
- Hematological Malignancies and Pneumococcal Disease Risk
- In CLL: The Association of Survival and Gammaglobulin Abnormalities
- Concordance of Leukemia Outcomes Among First-Degree Relatives
- CLL Patients Show Low Response to COVID-19 Vaccine, But Does Remission Improve Immunity?
- CLL and NHL Linked to Certain Skin Traits
- Q&A With Lindsey Roeker, MD: CLL and COVID-19 vaccine
- Chronic Lymphocytic Leukemia: What Families Can Tell Us
- CLL: Tracking a Marker of Progression
- CLL and Atrial Fibrillation: The Burden on Hospitalized Patients
- Q&A: CLL Prognostic Models
- Do Statins Improve Survival in Patients with Lymphoma?
- TP53 Gene Mutational Status Among Patients with CLL
- In CLL, Do These Biomarkers Tell a Story About Physical Fitness and Function?
- COVID-19 Vaccinations in Patients with Hematologic Malignancies
- Leukemias and Multiple Myeloma: Building Better Studies
- Chronic Lymphocytic Leukemia: A Closer Look at Clonal Cell Subpopulations
- Lymphoma Type May Affect Response to COVID Vaccination
- Emerging Technologies in CLL Laboratory Testing (2:33)
- COVID-19 Vaccination Strategies in Patients with CLL (2:50)
- What is the Evolving Role of Minimal Residual Disease Assessment in CLL?
- New Challenges in Managing Richter Transformation in the Era of Novel Agents
- In CLL, Navigating a ‘Watch and Wait’ Approach
- Molecular Testing in CLL
- Richter’s Transformation in CLL: What are the Risk Factors?
- In CLL, Using Intravenous Immunoglobulin
- Managing Shingles in CLL Patients
- PSA: EVOLVE CLL Study
- Q&A: Do CLL Patients Benefit from High-Intensity Interval Training? Resistance Training?